Latest market price
69.06
-1.96-2.76%
OverviewShort InterestFilings
WGSQT35GeneDx Holdings Corp.·NASDAQ
69.06-2.76%
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
PSNL-0.69%$15.82OPK+0.00%$1.66CSTL-3.51%$37.16VCYT-4.14%$50.01CDNA+22.22%$87.41SHC-2.94%$18.15BLLN-1.32%$113.32RDNT-0.22%$73.49
Snapshot
Index—P/E—EPS (ttm)-3.62Insider Own40.89%Shs Outstand29.82MPerf Week22.99%
Market Cap2.06BForward P/E57.61EPS next Y1.20Insider Trans25.16%Shs Float28.90MPerf Month-2.68%
Enterprise Value2.09BPEG—EPS next Q—Short Float20.84%Perf Quarter1.77%
Income-107.00MP/S4.54EPS this Y-92.64%Short Ratio8.30Perf Half Y5.63%
Sales454.00MP/B8.44EPS next Y1098.80%ROA-22.09%Short Interest6.02MPerf YTD-46.90%
Book/sh8.18P/C15.49EPS next 5Y167.30%ROE-38.72%52W High170.87 -59.58%Perf Year-47.59%
Cash/sh4.46P/FCF—EPS past 3/5Y—ROIC-14.69%52W Low32.21 114.41%Perf 3Y2179.21%
Dividend Est.—EV/EBITDA—Sales past 3/5Y22.12% 19.05%Gross Margin68.20%Volatility8.27% 7.82%Perf 5Y-72.43%
Dividend TTM—EV/Sales4.61EPS Y/Y TTM—Oper. Margin-13.34%ATR (14)5.73Perf 10Y—
Dividend Ex-Date—Quick Ratio3.06Sales Y/Y TTM25.07%Profit Margin-23.40%RSI (14)48.53Recom2.09
Dividend Gr. 3/5Y—Current Ratio3.30EPS Q/Q-98.00%SMA203.18%Beta2.01Target Price81.00
Payout0.00%Debt/Eq0.69Sales Q/Q10.68%SMA50-12.63%Rel Volume1.18Prev Close71.02
Employees1,300LT Debt/Eq0.66EarningsNov 09SMA200-3.99%Avg Volume749.35KPrice69.06
IPO DateNov 04, 2020Option/ShortYes / YesEPS/Sales Surpr.105.32% 3.09%Net Debt/EBITDA—Volume886,021Change-2.76%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-01-26ReiteratedGuggenheimBuy$74 → $83
Aug-04-26ReiteratedCanaccord GenuityBuy$75 → $90
Jun-29-26ReiteratedGuggenheimBuy$70 → $74
Jun-23-26ReiteratedPiper SandlerOverweight$130 → $63
May-05-26ReiteratedCraig-HallumBuy$153 → $85
May-05-26ReiteratedBTIGBuy$170 → $90
May-05-26ReiteratedCanaccord GenuityBuy$100 → $75
May-05-26ReiteratedWells FargoOverweight$155 → $75
May-05-26ReiteratedGuggenheimBuy$170 → $70
Apr-20-26ReiteratedCanaccord GenuityBuy$170 → $100
Latest News· Times ET
Oct-27-26
Oct-27-2603:28PM
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com
Oct-26-26
Oct-26-2606:23AM
Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On MondayBenzinga
Oct-23-26
Oct-23-2604:05PM
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026businesswire.com
Oct-20-26
Oct-20-2608:30AM
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosisbusinesswire.com
Oct-19-26
Oct-19-2604:05PM
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026businesswire.com
Oct-18-26
Oct-18-2602:21AM
GeneDx (NASDAQ:WGS) Stock Falls 5.5% – Here’s What Happeneddefenseworld.net
01:58AM
Analyzing GeneDx (NASDAQ:WGS) and LifeMD (NASDAQ:LFMD)defenseworld.net
Oct-17-26
Oct-17-2611:11AM
GeneDx Holdings And 2 Other Top Healthcare StocksYahoo
Oct-10-26
Oct-10-2610:17AM
Top 3 Healthcare Stocks To Watch In October 2026Yahoo
02:58AM
Comparing GeneDx (NASDAQ:WGS) & Brookdale Senior Living (NYSE:BKD)defenseworld.net
Oct-07-26
Oct-07-2611:08AM
Encompass Health Expands Rehab Footprint With New Maine HospitalYahoo
09:00AM
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026gurufocus.com
Oct-05-26
Oct-05-2608:36PM
GeneDx Holdings Corp (WGS) Shares Surge 4.3% -- What GF Score of 67 Tells Investorsgurufocus.com
Oct-02-26
Oct-02-2608:30AM
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Carebusinesswire.com
Oct-01-26
Oct-01-2605:46AM
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83Benzinga
Company

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue454428305203————
Cost of Goods Sold Incl. D&A144129111113————
Gross Profit31029819490————
Selling, General and Administrative Excl. Other292239168195————
Research and Development84724658————
Other Operating Expense-50418————
Operating Income-60-12-23-181————
Interest Expense4330————
Unusual Expense
————————
Non-Operating Income (Expense)-44-7-264————
Net Income Before Taxes-105-21-53-177————
Income Taxes100-1————
Consolidated Net Income-107-21-52-176————
Net Income From Continuing Operations-108-21-52-176————
Net Income-107-21-52-176————
EPS (Recurring)-3.64-0.73-1.94-7.23————
EPS (Basic, Before Extraordinaries)-3.64-0.73-1.94-7.23————
EPS (Diluted)-3.62-0.73-1.94-7.23————
EBITDA-767-28-136————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio4.568.206.800.33————
Gross Margin68.2869.6363.6144.33————
Operating Margin-13.22-2.80-7.54-89.16————
Net Margin-23.57-4.91-17.05-86.70————
Shares Outstanding30272724————
Market Capitalization2,0723,5122,07566————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$187.47$144.24$101.02$57.79$14.56● Close Price0.00M20.51M41.02M61.52M82.03MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fuchs ThomasDirectorSep 17 '26Option Exercise0.001,14601,146Sep 18
Stueland KatherineCHIEF EXECUTIVE OFFICERSep 16 '26Sale97.6110,5011,025,013115,476Sep 18
Feeley KevinCHIEF FINANCIAL OFFICERSep 16 '26Option Exercise0.007,197048,673Sep 18
Feeley KevinCHIEF FINANCIAL OFFICERSep 16 '26Sale97.613,728363,89244,945Sep 18
Stueland KatherineCHIEF EXECUTIVE OFFICERSep 16 '26Option Exercise0.0018,7500125,977Sep 18
Stueland KatherineCHIEF EXECUTIVE OFFICERSep 09 '26Option Exercise0.006,5470110,919Sep 11
Stueland KatherineCHIEF EXECUTIVE OFFICERSep 09 '26Sale84.223,692310,932107,227Sep 11
Feeley KevinCHIEF FINANCIAL OFFICERSep 09 '26Option Exercise0.002,462042,761Sep 11
Feeley KevinCHIEF FINANCIAL OFFICERSep 09 '26Sale84.221,285108,22041,476Sep 11
Feeley KevinCHIEF FINANCIAL OFFICERSep 01 '26Option Exercise0.00717040,671Sep 03
Feeley KevinCHIEF FINANCIAL OFFICERSep 01 '26Sale83.8437231,18840,299Sep 03
Ryan JasonDirectorJun 18 '26Option Exercise0.003,576015,480Jun 23
RUCH JOSHUADirectorJun 18 '26Option Exercise0.003,576033,299Jun 23
PFENNIGER RICHARD C JRDirectorJun 18 '26Option Exercise0.003,576045,082Jun 23
Meister Keith A.Director, 10% OwnerJun 18 '26Option Exercise0.003,576023,705Jun 23
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.